Astec LifeSciences Reports Widened Losses in Q2FY27 Amid Agrochemical Headwinds
Astec Lifesciences Ltd · Press Release · 27 Oct 2026, 12:37 am
Astec LifeSciences Reports Widened Losses in Q2FY27 Amid Agrochemical Headwinds Astec LifeSciences reported a 3% YoY decline in Q2FY27 consolidated total income to ₹72.6 crore, alongside a widened EBITDA loss of ₹19.2 crore versus a loss of ₹5.6 crore in Q2FY26. Net loss expanded to ₹37.4 crore from ₹24.4 crore YoY, impacted by subdued demand, lower realizations, elevated input costs, and an inventory write-down of ₹3 crore. Segmentally, enterprise revenue dropped 6% YoY to ₹57.0 crore, while CDMO grew 15% YoY to ₹15.0 crore. Geographically, domestic revenue rose 32% YoY to ₹43.1 crore, offset by a 30% export decline to ₹28.9 crore.
Original exchange filing (PDF)
More announcements from Astec Lifesciences Ltd
- Please find enclosed, Company''s response. · 12 Nov 2026
- The Exchange has sought clarification from Astec Lifesciences Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 11 Nov 2026
- Please find enclosed Financials Results for the Quarter and Half year ended . · 26 Oct 2026
- Astec LifeSciences Limited has informed the Exchange regarding Outcome of Board Meeting held on October 26, 2026. · 26 Oct 2026
- Kindly find attached Outcome of Board meeting · 26 Oct 2026
- Astec LifeSciences Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2026. · 26 Oct 2026
- ASTEC LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 26 Oct 2026
- Astec Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve Please find enclosed intimation. · 26 Oct 2026
